Single Nasal K3-SPG Dose Protects Mice From Lethal Flu 100 Days Later by Shifting Macrophage Then ILC Responses
K3-SPG nasal adjuvant induced durable, route-specific innate protection in mice against influenza and SARS-CoV-2 via sequential macrophage and ILC activation focused on tissue tolerance. Human translation remains untested and requires safety and pharmacokinetic data. Evidence is limited to mouse challenge models with incomplete quantitative endpoints.
No absolute survival percentages or hazard ratios were reported in the press summary, limiting precise effect-size interpretation. Next required studies are GLP toxicology in ferrets or nonhuman primates followed by a first-in-human ascending-dose trial measuring mucosal cytokine profiles and adverse events within 28 days of dosing.
Ishii group: First-in-human nasal K3-SPG safety study will report no grade-3 adverse events in the 0.1–1 mg cohort within 24 months.
Sources (2)
- [1]Primary Source(https://www.science.org/doi/10.1126/sciadv.adp2076)
- [2]Supporting Source(https://medicalxpress.com/news/2026-10-nasal-vaccine-additive-flu-survival.html)